Veopoz Injection, Solution
FDA Label NDC 61755-014

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Regeneron Pharmaceuticals, Inc. for the product Veopoz (NDC 61755-014). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious meningococcal infections, 1 indications and usage, 2.1 recommended vaccination and prophylaxis for meningococcal infection prior to first dose of veopoz, 2.2 recommended dosage and administration, other, 2.3 intravenous infusion loading dose: preparation and administration instructions, 2.4 subcutaneous maintenance dose: preparation and administration instructions, 2.5 recommendations regarding missed maintenance subcutaneous dose(s), and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Warning: Serious Meningococcal Infections

  • Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.
  • Complete or update meningococcal vaccination (for serogroups A, C, W and Y, and serogroup B) at least 2 weeks prior to administering the first dose of VEOPOZ, unless the risks of delaying therapy outweigh the risk of developing a meningococcal infection. Follow the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor.
  • Patients receiving VEOPOZ are at increased risk for invasive disease caused by N. meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected [see Warnings and Precautions (5.1)].

1 Indications And Usage

VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.

2.1 Recommended Vaccination And Prophylaxis For Meningococcal Infection Prior To First Dose Of Veopoz

  • Vaccinate patients for meningococcal infection (serogroups A, C, W, and Y [MenACWY] and serogroup B [MenB]) according to current ACIP recommendations for patients receiving a complement inhibitor at least 2 weeks prior to administering the first dose of VEOPOZ [see Warnings and Precautions (5.1)].
  • If urgent VEOPOZ therapy is indicated in a patient who is not up-to-date with vaccines for both MenACWY and MenB according to ACIP recommendations, administer meningococcal vaccine(s) as soon as possible and provide the patient with antibacterial drug prophylaxis. The efficacy, duration, and drug regimens for antibacterial drug prophylaxis have not been studied in patients receiving complement inhibitors, including VEOPOZ.

2.2 Recommended Dosage And Administration

The recommended dosage of VEOPOZ is as follows:

Other

Day 1 (Loading Dose):

Administer a single 30 mg/kg dose by intravenous infusion after dilution [see Dosage and Administration (2.3)].

Day 8 and Thereafter (Maintenance Dosage):

Inject 10 mg/kg as a subcutaneous injection once weekly starting on Day 8 [see Dosage and Administration (2.4)].

  • The maintenance dosage may be increased to 12 mg/kg once weekly if there is inadequate clinical response after at least 3 weekly doses (i.e., starting from Week 4).
  • The maximum maintenance dosage is 800 mg once weekly.
  • Doses greater than 400 mg require 2 injections.

    • Preparation Instructions for Intravenous Infusion Loading Dose

    • Remove VEOPOZ vial(s) from refrigeration and allow the vial(s) to sit for at least 45 minutes at room temperature 20°C to 25°C (68°F to 77°F) before use.
    • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. VEOPOZ should be a clear to slightly opalescent, colorless to pale yellow solution that is free from visible particulates. Discard the vial(s) if the solution is cloudy, discolored or contains particulate matter.
    • Gently swirl the vial(s) in an upright position. Do not shake the vial(s) as this may result in foaming.
    • Use a 21G stainless steel needle with Luer-Lok to withdraw the calculated volume of VEOPOZ from the vial(s). Discard any unused VEOPOZ remaining in the vial(s).
    • Dilute VEOPOZ in an intravenous infusion bag of 25 mL to 250 mL of either 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a final concentration of 6.7 mg/mL to 20 mg/mL.
    • Mix the diluted solution by gentle inversion. Do not shake.

      • Administration Instructions for Intravenous Infusion Loading Dose

      • Infuse through an intravenous line containing a sterile, in-line or add on 0.2-micron to 5-micron filter.
        • Infusion rate: infuse over a minimum of 1 hour; do not exceed maximum rate of 1000 mg/hour
        • Do not co-administer other medications through the same intravenous line
        • Observe the patient for 30 minutes following completion of the infusion [see Warnings and Precautions (5.3)].

          • Storage of Diluted Intravenous Solution

          • Administer the diluted VEOPOZ solution immediately after preparation. If not used immediately, store at room temperature up to 25°C (77°F) for no more than 8 hours from the time of preparation to the end of the infusion or refrigerate at 2°C to 8°C (36°F to 46°F) for no more than 24 hours from the time of preparation to the end of infusion.
          • If stored in the refrigerator, allow the diluted solution to come to room temperature prior to administration.
          • Discard the unused VEOPOZ diluted solution after 8 hours if stored at room temperature or after 24 hours if refrigerated.
          • Do not freeze the diluted solution.

            • Preparation Instructions for Subcutaneous Maintenance Dose

            • Remove VEOPOZ vial(s) from refrigeration and allow the vial(s) to sit for at least 45 minutes at room temperature 20°C to 25°C (68°F to 77°F) before use.
            • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. VEOPOZ should be a clear to slightly opalescent, colorless to pale yellow solution that is free from visible particulates. Discard the vial(s) if the solution is cloudy, discolored or contains particulate matter.
            • Gently swirl the vial(s) in an upright position. Do not shake the vial(s) as this may result in foaming.
            • Use a withdrawal needle (21G needle with Luer-Lok) to withdraw the calculated dose volume of VEOPOZ from the appropriate number of vial(s). Discard any unused VEOPOZ remaining in the vial(s).
              • For patients receiving a dose greater than 400 mg, preparation of 2 separate injections will be required for subcutaneous administration of the total dose volume.
              • Change the needle on the syringe to an injection needle fulfilling the following criteria: 25G to 27G and ½ or 5/8-inch stainless steel needle with Luer-Lok.

                • Administration Instructions for Subcutaneous Maintenance Dose

                • Inject VEOPOZ into the abdomen, thigh, or upper arm. Rotate sites. Do not inject VEOPOZ into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. When administering more than one injection, administer consecutively, each at different injection sites.
                • Observe the patient for 30 minutes following completion of the first subcutaneous injection [see Warnings and Precautions (5.3)].

                  • Storage of Subcutaneous Injection

                  Administer the subcutaneous injection within 4 hours of preparation.

                  Vital Signs:

                  Four patients reported elevated systolic and/or diastolic blood pressure readings above the normal range for age at multiple study visits.

                  Risk Summary

                  Although there are no data on VEOPOZ use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, monoclonal antibodies can be actively transported across the placenta.

                  In an animal reproduction study in monkeys, pozelimab-bbfg did not adversely affect embryofetal or postnatal development when administered from pregnancy confirmation through parturition at doses that produced exposure up to 3.3 to 3.8 times the predicted clinical exposures (on an AUC basis; see Data).

                  The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other outcome. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

                  Data

                  Animal Data

                  In an enhanced pre- and postnatal development study, pregnant female monkeys were subcutaneously administered pozelimab-bbfg at doses of 5 or 50 mg/kg once weekly from confirmation of pregnancy (gestation day 20) through parturition (approximately gestation day 160). No adverse effects were observed on maintenance of pregnancy, pregnancy outcome, or on the development of offspring through postnatal day 90 at doses up to 3.3-3.8 times the predicted clinical exposures.

                  Risk Summary

                  There are no data on the presence of pozelimab-bbfg in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred into human milk. The effects of local gastrointestinal exposure and the extent of systemic exposure in the breastfed infant to pozelimab are unknown. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for VEOPOZ and any potential adverse effects on the breastfed infant from VEOPOZ or from the underlying maternal condition.

                  Absorption

                  In healthy subjects, following subcutaneous injection of 600 mg, the bioavailability of pozelimab-bbfg is estimated as 51%. The median (range) time to reach peak concentration was 7 (3 to 7) days following a single subcutaneous injection of 300 mg or 600 mg in healthy subjects.

                  Distribution

                  In healthy adult subjects with a mean body weight of 70 kg, the mean (SD) volume of distribution following a single intravenous dose of 30 mg/kg was 3.3 (0.4) L. The mean (SD) apparent volume of distribution following a single subcutaneous injection of 300 mg and 600 mg was 6.0 (0.9) L and 8.6 (2.7) L, respectively.

                  Elimination

                  Pozelimab-bbfg is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG. Pozelimab-bbfg elimination is mediated via linear and non-linear pathways. At higher concentrations, pozelimab-bbfg elimination is primarily through the linear non-saturable proteolytic pathway, whereas at lower concentrations, the non-linear, saturable C5 target-mediated elimination predominates.

                  In healthy adult subjects, the median (range) terminal half-life of total pozelimab in serum was 13.5 (10.0, 17.2) days following a single 30 mg/kg dose administered as an intravenous infusion. The median (range) terminal half-life was 14.1 (8.6, 17.3) days following a single 600 mg subcutaneous injection.

                  In patients with CD55-deficient PLE, steady-state total pozelimab concentrations were reached at approximately 20 weeks following subcutaneous injection once weekly.

                  Specific Populations

                  Body Weight

                  Body weight was a significant covariate on the pharmacokinetics of pozelimab-bbfg.

                  Renal and Hepatic Impairment

                  Pozelimab-bbfg, a monoclonal antibody, is not likely to undergo renal or hepatic excretion.

                  Drug Interaction Studies

                  Drug interaction studies have not been conducted. Intravenous Immunoglobulin (IVIg) may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as pozelimab-bbfg, which may decrease serum pozelimab concentrations [see Drug Interactions (7.1)].

                  Carcinogenesis and Mutagenesis

                  Carcinogenicity studies have not been conducted with pozelimab-bbfg. The mutagenic potential of pozelimab-bbfg has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes.

                  Impairment of Fertility

                  Fertility studies have not been conducted with pozelimab-bbfg. In a 6-month toxicity study in sexually-mature male and female monkeys, pozelimab-bbfg had no adverse effects on histological or functional markers of reproductive function (e.g., estrous cyclicity, testicular volume, ejaculate amount, total sperm count per ejaculate, sperm motility and morphology, and histology of reproductive organs) at doses up to 100 mg/kg/week (11.9 to 13.9-fold the predicted exposures at the recommended clinical doses, on an AUC basis).

                  Serum Albumin Concentrations

                  The median time for serum albumin to reach at least 3.5 g/dL was 15.5 days (N=10; 95% CI: 8 to 28). All 10 patients achieved normalization by Week 12 and maintained serum albumin concentrations within the normal range through at least 72 weeks of treatment (Figure 1).

                  Figure 1: Serum Albumin Concentrations from 48 Weeks Pre-Treatment Through 72 Weeks on VEOPOZ in Ten Patients with CD-55 Deficient PLE

                  Figure 1 (Pozelimab 01)

                  Figure 1 (Pozelimab 01)

                  Albumin Transfusions

                  Five of the 10 patients received a total of 60 transfusions in the 48 weeks prior to treatment. In the 48 weeks after starting treatment, one patient received one albumin transfusion.

                  Hospitalizations

                  Nine of the 10 patients were hospitalized for a total of 268 days in the 48 weeks prior to treatment. In the 48 weeks after starting treatment, two patients were hospitalized for a total of 7 days.

                  Additional Efficacy Results

                  Serum IgG concentrations reached normal values for age in all patients within the first 12 weeks of treatment; improvement was maintained through at least 72 weeks of treatment.

                  Meningococcal Infection

                  • Advise patients of the risk of meningococcal, and other bacterial infections.
                  • Inform patients of the need to complete or update meningococcal vaccination for both MenACWY and MenB at least 2 weeks prior to receiving the first dose of VEOPOZ and to be revaccinated according to current ACIP recommendations for meningococcal vaccines while on VEOPOZ therapy.
                  • Inform patients that vaccination may not prevent meningococcal infection.
                  • Inform patients of the signs and symptoms of meningococcal infection and advise patients to seek immediate medical attention if any signs or symptoms of infection occur [see Warnings and Precautions (5.1)].

                    • Other Bacterial Infections, Including Gonococcal Infection

                    • Inform patients of the increased risk of other bacterial infections, particularly those due to encapsulated bacteria.
                    • Inform patients of the need to receive vaccinations according to the ACIP recommendations.
                    • Advise patients to report any new signs and symptoms of infection.
                    • Counsel patients about gonorrhea prevention and advise patients at risk (e.g., sexually active) to seek regular testing [see Warnings and Precautions (5.2)].

                      • Systemic Hypersensitivity Reactions

                      Advise patients to notify the healthcare provider and seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions [see Warnings and Precautions (5.3)].

                      Manufactured by:

                      Regeneron Pharmaceuticals, Inc.
                      777 Old Saw Mill River Road
                      Tarrytown, NY 10591-6707
                      U.S. License No. 1760

                      Marketed by:

                      Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)
                      ©2023 Regeneron Pharmaceuticals, Inc.

                      All rights reserved.

2.3 Intravenous Infusion Loading Dose: Preparation And Administration Instructions

VEOPOZ for intravenous use must be prepared and administered by a healthcare provider.

2.4 Subcutaneous Maintenance Dose: Preparation And Administration Instructions

VEOPOZ for subcutaneous use must be prepared and administered by a healthcare provider.

2.5 Recommendations Regarding Missed Maintenance Subcutaneous Dose(S)

If a subcutaneous maintenance dose of VEOPOZ is missed, administer as soon as possible within 3 days after the missed dose. Do not administer 2 doses on the same day to make up for a missed dose. If more than 3 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.

The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 4 days (96 hours).

3 Dosage Forms And Strengths

Injection: 400 mg/2 mL (200 mg/mL) as a clear to slightly opalescent, colorless to pale yellow solution in a single-dose vial.

5.1 Serious Meningococcal Infections

Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The use of VEOPOZ increases a patient's susceptibility to serious and life-threatening meningococcal infections (septicemia and/or meningitis) caused by any serogroup, including nongroupable strains.

Complete or update meningococcal vaccination (for serogroups A, C, W, and Y [MenACWY] and serogroup B [MenB]) at least 2 weeks prior to administering the first dose of VEOPOZ, according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of VEOPOZ therapy.

If urgent VEOPOZ therapy is indicated in a patient who is not up-to-date with both MenACWY and MenB vaccines according to ACIP recommendations, administer meningococcal vaccine(s) as soon as possible and provide the patient with antibacterial drug prophylaxis. The efficacy, duration, and drug regimens for antibacterial drug prophylaxis have not been studied in patients receiving complement inhibitors.

Because of inhibition of complement activity by VEOPOZ, as well as risk of infection caused by nongroupable strains of N. meningitidis, vaccination does not eliminate the risk of meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients and caregivers of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Interrupt treatment with VEOPOZ in patients who are undergoing treatment for serious meningococcal infection until the infection is resolved [see Contraindications (4)].

5.2 Other Bacterial Infections

VEOPOZ blocks terminal complement activation; therefore, patients may have increased susceptibility to encapsulated bacterial infections, especially infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Patients treated with VEOPOZ may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP guidelines. Patients receiving VEOPOZ are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination. Interrupt treatment with VEOPOZ in patients who are undergoing treatment for a serious encapsulated bacterial infection until the infection is resolved. Counsel patients about gonorrhea prevention and advise regular testing for patients at risk.

5.3 Systemic Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported with administration of complement inhibitors. Interrupt VEOPOZ and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

5.4 Immune Complex Formation

Immune complex formation has been reported during the transition of therapy between complement inhibitors, resulting in transient decrease in drug concentrations as well as symptoms suggestive of hypersensitivity reactions. However, this has not been studied in patients with CD55-deficient PLE switching from other complement inhibitors to pozelimab. The potential for immune complex formation should be considered if switching complement inhibitors.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of VEOPOZ was evaluated in 10 patients with CD55-deficient PLE (ranging from 3 to 19 years of age) in a single-arm study [see Clinical Studies (14)]. The median duration of exposure was 104 weeks (range: 75 to 140 weeks). Adverse reactions reported in two or more patients are summarized in Table 1.

Table 1: Adverse Reactions Reported in Two or More VEOPOZ-Treated Patients with CD55-deficient PLE in a Clinical Trial
Adverse ReactionsVEOPOZ
N=10
n (%)
Upper respiratory tract infection

Composed of similar terms

3 (30)
Fracture3 (30)
Urticaria2 (20)
Alopecia2 (20)

Additionally, injection site reactions (including dermatitis and erythema), metabolic acidosis, gingival bleeding, increased blood uric acid, increased liver enzymes, hematuria and proteinuria were reported in one patient each.

7.1 Intravenous Immunoglobulin

VEOPOZ has not been studied in combination with intravenous immunoglobulin. Intravenous immunoglobulin may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as pozelimab thereby decrease serum pozelimab concentrations. Avoid concomitant use of intravenous immunoglobulin with VEOPOZ. If concomitant use cannot be avoided, monitor patients for worsening of clinical signs and symptoms of CD55-deficient PLE [see Clinical Pharmacology (12.3)].

8.4 Pediatric Use

The safety and effectiveness of VEOPOZ for the treatment of CD55-deficient PLE have been established in pediatric patients 1 year of age and older. Use of VEOPOZ for this indication is supported by a single-arm study in 10 patients with active CD55-deficient PLE [see Adverse Reactions (6.1) and Clinical Studies (14)].

The safety and effectiveness of VEOPOZ have not been established in pediatric patients less than 1 year of age.

8.5 Geriatric Use

CD55-deficient PLE is largely a disease of pediatric patients. VEOPOZ has not been studied in the geriatric population.

11 Description

Pozelimab-bbfg, a complement inhibitor, is a recombinant monoclonal antibody (IgG4 isotype). Pozelimab-bbfg is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture and has an approximate molecular weight of 145 kDa.

VEOPOZ (pozelimab-bbfg) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution supplied in a single-dose glass vial, free from visible particulates, for intravenous or subcutaneous use. Each vial contains 400 mg pozelimab-bbfg in 2 mL of solution with a pH of 5.8. Each mL contains 200 mg pozelimab-bbfg, arginine hydrochloride (21 mg), histidine (1.15 mg), L-histidine hydrochloride monohydrate (2.65 mg), polysorbate 80 (1.5 mg), sucrose (20 mg), and Water for Injection, USP.

12.1 Mechanism Of Action

Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4P) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).

12.2 Pharmacodynamics

The effect of pozelimab-bbfg on complement activity was measured by total complement hemolytic activity test (CH50). The magnitude and duration of reduction from baseline in CH50 by pozelimab-bbfg was dose dependent.

In healthy subjects receiving a single dose of VEOPOZ 30 mg/kg administered as an intravenous infusion over approximately one hour, the complete inhibition of CH50 was achieved at the end of infusion in all subjects, was maintained for 28 days, and returned to baseline 84 days post-dose. After a single dose of VEOPOZ administered as a 600 mg subcutaneous injection, the maximum reduction from baseline in CH50 was achieved 7 days post-dose in most subjects (range: 3 to 14 days), corresponding to Tmax, and returned to baseline 56 days post-dose.

In patients with CD55-deficient PLE receiving a single 30 mg/kg dose administered as an intravenous infusion over approximately one hour followed by a weight-tiered subcutaneous injection once weekly starting at Week 1, CH50 was completely inhibited by Week 1 for most subjects and by Week 12 for all patients.

In the same study of patients with CD55-deficient PLE, serum albumin concentrations increased as early as Week 1 and reached the normal range (≥3.5 g/dL) by Week 4 for most subjects and by Week 12 for all subjects. The serum albumin concentrations were maintained within the normal range for the duration of treatment. Endogenous serum IgG concentrations were also increased from baseline at Week 1 in all patients with CD55-deficient PLE and reached a stable concentration around Week 16 [see Clinical Studies (14)].

12.3 Pharmacokinetics

In healthy subjects, single intravenous infusions of VEOPOZ over approximately one hour resulted in dose proportional increases in mean Cmax, but greater than proportional increases in mean AUCinf (>16-fold) for total pozelimab concentrations in serum between 3 mg/kg and 30 mg/kg. The mean AUCinf increased by 3.5-fold between 10 mg/kg and 30 mg/kg. In healthy subjects, single subcutaneous injections of VEOPOZ resulted in approximately 1.5-fold increase in mean Cmax and 2.2-fold increase in mean AUCinf between 300 mg and 600 mg.

In patients with CD55-deficient PLE, a single dose of VEOPOZ 30 mg/kg administered as an intravenous infusion over approximately one hour resulted in median (range) total pozelimab trough concentration of 180 (52.8, 268) mg/L at Week 1. The predicted mean (SD) trough concentrations of total pozelimab at steady state are 330 (94.2) mg/L and 385 (112) mg/L for VEOPOZ 10 mg/kg or 12 mg/kg (up to a maximum 800 mg) once weekly via subcutaneous injection(s), respectively, following the intravenous loading dose.

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies, including those of VEOPOZ or of other pozelimab products.

Nine of the 10 patients 3 years of age and older with CD55-deficient PLE in the clinical study were evaluable for anti-pozelimab antibodies. None of these patients developed anti-pozelimab-bbfg antibodies during the 48-week treatment with pozelimab-bbfg. There is insufficient information to characterize the effect of anti-drug antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of pozelimab.

14 Clinical Studies

The efficacy and safety of VEOPOZ were evaluated in a single-arm study (NCT04209634) where outcomes were compared to pre-treatment data in patients with active CD55-deficient protein-losing enteropathy (PLE) who had hypoalbuminemia. Diagnosis was based on a clinical history of PLE and with a confirmed genotype of biallelic CD55 loss-of-function mutation.

Active CD55-deficient PLE was defined as hypoalbuminemia (serum albumin concentration of ≤3.2 g/dL) with one or more of the following signs or symptoms within the last six months: abdominal pain, diarrhea, peripheral edema, or facial edema.

Patients received a single 30 mg/kg loading dose of VEOPOZ administered by intravenous infusion over approximately one hour, followed by a once weekly weight-tiered maintenance dosage, administered as a subcutaneous injection starting one week after the loading dose.

All patients received meningococcal vaccination prior to treatment with VEOPOZ and antibacterials for prophylaxis of meningococcal infection. Patients were permitted to receive additional therapies as part of standard of care. Use of other complement inhibitors was prohibited.

Ten patients ranging from 3 to 19 years of age (median of 8.5 years) were assessed for efficacy. Six patients identified as female; seven patients as White, two patients as Asian, and one patient reported race as other. The mean baseline serum albumin concentration was 2.2 g/dL with a range of 1.1 to 2.9 g/dL.

16 How Supplied/Storage And Handling

VEOPOZ (pozelimab-bbfg) injection is a clear to slightly opalescent, colorless to pale yellow solution. It is supplied in a carton containing one single-dose glass vial of:

  • 400 mg/2 mL (200 mg/mL) (NDC 61755-014-01).

Storage And Handling

Store VEOPOZ vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. Discard unused portion.

17 Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Inform patients that they will be given a Patient Safety Card for VEOPOZ that they should carry with them at all times. This card describes symptoms of meningococcal, or other infection, which, if experienced, should prompt the patient to seek immediate medical evaluation.

Spl Medguide

This Medication Guide has been approved by the U.S. Food and Drug Administration.Issued: 08/2023  
MEDICATION GUIDE
VEOPOZ™ (VEE-oh-poz)
(pozelimab-bbfg)
injection, for intravenous or subcutaneous use
What is the most important information I should know about VEOPOZ?
VEOPOZ is a medicine that affects your immune system. VEOPOZ can lower the ability of your immune system to fight infections.
  • VEOPOZ increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.
  • You must receive meningococcal vaccines at least 2 weeks before your first dose of VEOPOZ if you have not already had these vaccines.
  • If you had a meningococcal vaccine in the past, you might need additional vaccination before starting VEOPOZ. Your healthcare provider will decide if you need additional meningococcal vaccination.
  • If your healthcare provider decided that urgent treatment with VEOPOZ is needed, and your meningococcal vaccines are not up-to-date, you should receive meningococcal vaccination as soon as possible. You should also receive antibiotics.
  • Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
  • headache with nausea or vomiting
  • headache with a stiff neck or stiff back
  • fever and a rash
  • muscle aches with flu-like symptoms
  • headache and fever
  • fever
  • confusion
  • eyes sensitive to light
Your healthcare provider will give you a Patient Safety Card about the symptoms of meningococcal, or other infection. Carry it with you at all times during treatment and for 3 months after your last VEOPOZ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of VEOPOZ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
VEOPOZ may also increase the risk of other types of serious bacterial infections.
  • People who take VEOPOZ may have an increased risk of getting infections caused by Streptococcus pneumoniae and Haemophilus influenzae.
  • Certain people may also have an increased risk of bacterial infections including gonorrhea infection. Talk to your healthcare provider to find out if you are at risk of gonorrhea infection, about gonorrhea prevention, and regular testing.
    • Call your healthcare provider right away if you have any new signs or symptoms of infection.
What is VEOPOZ?
VEOPOZ is a prescription medicine called a monoclonal antibody. VEOPOZ is used to treat adults and children 1 year of age and older with a disease called CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
It is not known if VEOPOZ is safe and effective in children younger than 1 year of age.
Do not receive VEOPOZ if you:
  • have a meningococcal infection.
Before you receive VEOPOZ, tell your healthcare provider about all of your medical conditions, including if you:
  • have an infection or fever.
  • are pregnant or plan to become pregnant. It is not known if VEOPOZ will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if VEOPOZ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with VEOPOZ.
    • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    It is important that you:
    • have all recommended vaccinations before you start VEOPOZ.
    • receive antibiotics if you start VEOPOZ within 2 weeks of receiving meningococcal vaccination.
    • stay up to date with all recommended vaccinations during treatment with VEOPOZ.
      • VEOPOZ and other medicines may affect each other causing side effects. VEOPOZ may affect the way other medicines work, and other medicines may affect how VEOPOZ works.
      Especially tell your healthcare provider if you take Intravenous Immunoglobulin (IVIg).
      Know the medicines you take and the vaccines you receive. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I receive VEOPOZ?
  • The first dose of VEOPOZ is given through a vein (I.V. or intravenous infusion) usually over 1 hour or more, depending on your weight. If you have an allergic reaction during your VEOPOZ infusion, your healthcare provider may decide to give VEOPOZ more slowly or stop your infusion.
  • You will then receive VEOPOZ one time each week starting on day 8 after the first dose, as an injection under the skin (subcutaneous injection).
  • After the infusion and your first subcutaneous injection, you will be monitored for 30 minutes for allergic reactions.
  • If you miss receiving a VEOPOZ subcutaneous dose, call your healthcare provider right away to find out when you will receive your next injection.
What are the possible side effects of VEOPOZ?
VEOPOZ can cause serious side effects including:
  • See "What is the most important information I should know about VEOPOZ?"
  • Allergic (hypersensitivity) reactions. Allergic reactions, including infusion-related reactions, may happen during your VEOPOZ intravenous or subcutaneous treatment. Tell your healthcare provider right away if you develop the following symptoms, or any other symptoms during your VEOPOZ treatment that may mean you are having a serious allergic reaction:
  • chest pain
  • trouble breathing or shortness of breath
  • swelling of your face, tongue, or throat
  • feel faint or pass out
The most common side effects of VEOPOZ are:
  • upper respiratory tract infection
  • hair loss (alopecia)
  • fracture
  • raised, red patches of skin that are often very itchy (hives)
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of VEOPOZ. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of VEOPOZ.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about VEOPOZ that is written for health professionals.
What are the ingredients in VEOPOZ?
Active ingredient: pozelimab-bbfg.
Inactive ingredients: arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection.
Manufactured by:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591 U.S. License No. 1760
© 2023 Regeneron Pharmaceuticals, Inc.
All rights reserved.
For more information about VEOPOZ, go to www.VEOPOZ.com or call 1-855-5VEOPOZ (1-855-583-6769).

Principal Display Panel - 2 Ml Vial Carton

NDC 61755-014-01

Rx only

Veopoz™
(pozelimab-bbfg)
Injection

400 mg/2 mL (200 mg/mL)

For Intravenous Infusion after Dilution or
Subcutaneous Use

Dispense the enclosed Medication Guide to each patient.

Must dilute before intravenous infusion.

Single-Dose Vial. Discard Unused Portion.

One 2 mL Vial

REGENERON

Principal Display Panel (2 mL Vial Carton)

Principal Display Panel (2 mL Vial Carton)

* Please review the disclaimer below.